TY - JOUR
T1 - BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma
AU - Laviv, Yosef
AU - Toledano, Helen
AU - Michowiz, Shalom
AU - Dratviman-Storobinsky, Olga
AU - Turm, Yuval
AU - Fichman-Horn, Suzana
AU - Kagnovski, Ella
AU - Goldenberg-Cohen, Nitza
N1 - Funding Information:
This study was partially supported by the Zanvyl and Isabelle Krieger Fund, Baltimore, Maryland, USA; the Eldor-Metzner Clinician Scientist Award, Chief Scientist, Israel Ministry of Health (N.G.C., Grant No. 3-3741); and the Young Investigator Award, Rabin Medical Center, Petach Tikva, Israel (Y.L).
PY - 2012
Y1 - 2012
N2 - Fifty-two samples of pediatric low-grade glioma (48 primary, 4 recurrent) were analyzed for BRAF copy number variation (digital PCR analysis, CopyCaller) and point mutations of BRAF V600E, and exon 5 Q209 in GNAQ, and GNA11, using the MALDI-TOF mass spectrometer with validation by direct sequencing. An increased BRAF copy number was found in 18/47 primary samples tested; 15 of them (83.3%) were pilocytic astrocytomas. A BRAF mutation was found in 3/48 primary tumors, all with a normal BRAF copy number and no GNAQ mutation. One sample had a GNAQ209 mutation (Q209P626) with a normal BRAF gene. ; none of the tumors had a GNA11Q209 mutation. Recurrent or progressive tumors, analyzed in four patients, had the same molecular genotype as their primary. Increased BRAF copy number and activating BRAF mutations may be involved in the development of low-grade glioma via overactivation of the Ras/Raf pathway. This is the first report of a mutation in GNAQ209 in pediatric low-grade glioma. Understanding the molecular mechanisms underlying glioma initiation and growth may assist in the development of targeted therapies.
AB - Fifty-two samples of pediatric low-grade glioma (48 primary, 4 recurrent) were analyzed for BRAF copy number variation (digital PCR analysis, CopyCaller) and point mutations of BRAF V600E, and exon 5 Q209 in GNAQ, and GNA11, using the MALDI-TOF mass spectrometer with validation by direct sequencing. An increased BRAF copy number was found in 18/47 primary samples tested; 15 of them (83.3%) were pilocytic astrocytomas. A BRAF mutation was found in 3/48 primary tumors, all with a normal BRAF copy number and no GNAQ mutation. One sample had a GNAQ209 mutation (Q209P626) with a normal BRAF gene. ; none of the tumors had a GNA11Q209 mutation. Recurrent or progressive tumors, analyzed in four patients, had the same molecular genotype as their primary. Increased BRAF copy number and activating BRAF mutations may be involved in the development of low-grade glioma via overactivation of the Ras/Raf pathway. This is the first report of a mutation in GNAQ209 in pediatric low-grade glioma. Understanding the molecular mechanisms underlying glioma initiation and growth may assist in the development of targeted therapies.
KW - BRAF mutation
KW - Copy number variation
KW - GNAQ/GNA11
KW - Low-grade glioma
KW - Pediatric
UR - http://www.scopus.com/inward/record.url?scp=84862288835&partnerID=8YFLogxK
U2 - 10.1016/j.fob.2012.05.004
DO - 10.1016/j.fob.2012.05.004
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84862288835
SN - 2211-5463
VL - 2
SP - 129
EP - 134
JO - FEBS Open Bio
JF - FEBS Open Bio
ER -